Onconova Therapeutics Profit Margin

The latest profit margin for ONTX is 328309.64% as of June 2026. That compares with -9559.29% in the prior-year period — up 3534.5% year over year. That is above the Healthcare sector average of 10.58%. Investors often review this figure alongside Onconova Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ONTX's profit margin moved from -9559.29% to 328309.64% — a 3534.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Onconova Therapeutics's valuation or profitability profile.

Against Healthcare companies, ONTX currently prints 328309.64% for profit margin, while the sector average sits near 10.58%. That is roughly 3102878.1% above the sector mean. Large gaps often invite a closer look at Onconova Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Onconova Therapeutics converts resources into returns. At 328309.64%, ONTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -9559.29% in the prior-year period — up 3534.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ONTX's profit margin (328309.64%), review year-over-year change from -9559.29%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.